A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMvoke010
- Sponsors Roche
- 18 Jul 2019 Planned End Date changed from 28 Apr 2025 to 1 Feb 2025.
- 03 Apr 2019 Trial design presented at the 110th Annual Meeting of the American Association for Cancer Research
- 19 Mar 2018 Status changed from not yet recruiting to recruiting.